Key facts
- It has raised $107.8M; the latest was Later Stage VC ($54.2M) in Apr 2025.
- Notable investors include Noshaq, Federal Holding and Investment Company (Brussels), China Resources Capital Management, New Science Ventures, Société Régionale d'Investissement de Wallonie — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for NOVADIP
- ·The full record, as it builds
Funding rounds
No funding rounds for NOVADIP are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NOVADIP
Developer of cell-based regeneration therapies designed to develop a new class of regenerative tissue products to accelerate the healing of large bone defects, bone non-union, and spine fusion in a single treatment. The company's allogeneic product employs a matrix containing multiple bioactive factors that induce accelerated tissue healing, enabling doctors and patients to get positive clinical outcomes and long-term quality of life.
- Sector
- Healthcare
- HQ
- Mont-Saint-Guibert, Belgium
- Founded
- 2013
- Employees
- 45
- Website
- novadip.com/
- Ownership
- Privately Held (backing)
NOVADIP doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOVADIP shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOVADIP in its N-PORT filings yet. We sweep new filings monthly.